Stephen R Marder

Stephen R Marder

UNVERIFIED PROFILE

Are you Stephen R Marder?   Register this Author

Register author
Stephen R Marder

Stephen R Marder

Publications by authors named "Stephen R Marder"

Are you Stephen R Marder?   Register this Author

99Publications

2329Reads

9Profile Views

Evaluating visual neuroplasticity with EEG in schizophrenia outpatients.

Schizophr Res 2019 Aug 19. Epub 2019 Aug 19.

Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, CA, United States of America; Mental Illness Research, Education and Clinical Center (MIRECC), Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.schres.2019.08.015DOI Listing
August 2019

Brain glutathione levels and age at onset of illness in chronic schizophrenia.

Acta Neuropsychiatr 2019 Jul 31:1-5. Epub 2019 Jul 31.

VISN22 Mental Illness Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/neu.2019.29DOI Listing
July 2019

N-acetylcysteine improves EEG measures of auditory deviance detection and neural synchronization in schizophrenia: A randomized, controlled pilot study.

Schizophr Res 2019 Jun 31;208:479-480. Epub 2019 Jan 31.

VISN22 MIRECC Greater Los Angeles Veterans Affairs Healthcare System, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.schres.2019.01.036DOI Listing
June 2019

History of Psychopharmacology.

Annu Rev Clin Psychol 2019 May 20;15:25-50. Epub 2019 Feb 20.

Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, California 90095-1759, USA; email:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-clinpsy-050718-095514DOI Listing
May 2019

39 Long-term Safety and Tolerability of Once-Daily Valbenazine in Patients with Tardive Dyskinesia.

CNS Spectr 2019 Feb;24(1):196

6Executive Director,Medical Affairs,Neurocrine Biosciences,Inc.,San Diego,CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S1092852919000324DOI Listing
February 2019

A dose-finding study of oxytocin using neurophysiological measures of social processing.

Neuropsychopharmacology 2019 01 28;44(2):289-294. Epub 2018 Jul 28.

Mental Illness Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41386-018-0165-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300532PMC
January 2019

Reliability and validity of the self-report version of the apathy evaluation scale in first-episode Psychosis: Concordance with the clinical version at baseline and 12 months follow-up.

Psychiatry Res 2018 09 31;267:140-147. Epub 2018 May 31.

Clinic of mental health and addiction, Oslo University Hospital, Ulleval, Oslo 0407, Norway; NORMENT KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo 0318, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.psychres.2018.05.065DOI Listing
September 2018

"Will I need to take these medications for the rest of my life?"

World Psychiatry 2018 Jun;17(2):165-166

Desert Pacific Mental Illness Research, Education, and Clinical Center, Semel Institute for Neuroscience at UCLA, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/wps.20519DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980574PMC
June 2018

A 10-minute measure of global cognition: Validation of the Brief Cognitive Assessment Tool for Schizophrenia (B-CATS).

Schizophr Res 2018 05 13;195:327-333. Epub 2017 Sep 13.

Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, United States; Department of Psychology, UCLA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.schres.2017.08.033DOI Listing
May 2018

The effects of curcumin on brain-derived neurotrophic factor and cognition in schizophrenia: A randomized controlled study.

Schizophr Res 2018 05 29;195:572-573. Epub 2017 Sep 29.

Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA, USA; Mental Illness Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.schres.2017.09.046DOI Listing
May 2018

The Importance of Adequately Powered Clinical Studies: Response to Khan et al.

Am J Psychiatry 2018 02;175(2):188-189

From the Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles; the VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles; Laughren Psychopharmacology Consulting, Rockville, Md.; and Mallinckrodt Pharmaceuticals, St. Louis.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1176/appi.ajp.2017.17091016rDOI Listing
February 2018

Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes.

J Psychiatr Res 2017 12 8;95:299-307. Epub 2017 Sep 8.

Semel Institute for Neuroscience at UCLA, Los Angeles, CA, United States; VA Greater Los Angeles, Los Angeles, CA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpsychires.2017.09.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653420PMC
December 2017

Disparity between General Symptom Relief and Remission Criteria in the Positive and Negative Syndrome Scale (PANSS): A Post-treatment Bifactor Item Response Theory Model.

Innov Clin Neurosci 2017 Dec;14(11-12):41-53

Dr. Anderson is with the Department of Psychiatry and Biobehavioral Sciences and the Department of Statistics.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788250PMC
December 2017

Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies.

Acta Neuropsychiatr 2017 Oct 16;29(5):278-290. Epub 2016 Nov 16.

3Otsuka Pharmaceutical Development & Commercialization Inc.,Princeton,NJ,USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/neu.2016.57DOI Listing
October 2017

Why Are Innovative Drugs Failing in Phase III?

Am J Psychiatry 2017 Sep;174(9):829-831

From the Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles; the VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles; Laughren Psychopharmacology Consulting, Rockville, Md.; and Mallinckrodt Pharmaceuticals, St. Louis.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1176/appi.ajp.2017.17040426DOI Listing
September 2017

Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies.

Biol Psychiatry 2017 07 15;82(1):8-16. Epub 2016 Dec 15.

Desert Pacific Mental Illness Research, Education, and Clinical Center, Semel Institute for Neuroscience & Human Behavior, University of California, Los Angeles, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopsych.2016.11.014DOI Listing
July 2017

Improving measurement of attributional style in schizophrenia; A psychometric evaluation of the Ambiguous Intentions Hostility Questionnaire (AIHQ).

J Psychiatr Res 2017 06 9;89:48-54. Epub 2017 Jan 9.

University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Australian Catholic University, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpsychires.2017.01.004DOI Listing
June 2017

Why Are Innovative Drugs Failing in Phase III?

Am J Psychiatry 2017 Sep;174(9):829-831

From the Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles; the VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles; Laughren Psychopharmacology Consulting, Rockville, Md.; and Mallinckrodt Pharmaceuticals, St. Louis.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1176/appi.ajp.2017.17040426DOI Listing
September 2017

KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.

Am J Psychiatry 2017 05 21;174(5):476-484. Epub 2017 Mar 21.

From the Departments of Neurology and Molecular Pharmacology and Physiology, University of South Florida, Tampa; the Department of Neurology, Emory University, Atlanta; the Department of Psychiatry, University of California, Los Angeles; University Hills Clinical Research, Irving, Tex.; the Department of Psychology, Long Island University, New York; and Neurocrine Biosciences, Inc., San Diego.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1176/appi.ajp.2017.16091037DOI Listing
May 2017

A Cruel Irony for Clinicians Who Treat Depression.

Am J Psychiatry 2017 05;174(5):409-410

From the Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles; and the VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Long Beach, Calif.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1176/appi.ajp.2016.16111315DOI Listing
May 2017

How Occupationally High-Achieving Individuals With a Diagnosis of Schizophrenia Manage Their Symptoms.

Psychiatr Serv 2017 Apr 15;68(4):324-329. Epub 2016 Nov 15.

Dr. Cohen and Dr. Marder are with the Desert Pacific Mental Illness Research, Education and Clinical Center, Dr. Hamilton and Ms. Glover are with the Center for the Study of Healthcare Innovation, Implementation, and Policy, and Dr. Glynn is with the Research Service, all at the Greater Los Angeles Department of Veterans Affairs Healthcare System, Los Angeles (e-mail: ). Dr. Cohen, Dr. Hamilton, Dr. Glynn, and Dr. Marder are also with the Department of Psychiatry and Biobehavioral Sciences, The David Geffen School of Medicine, University of California, Los Angeles. Ms. Glover is also with the California School of Professional Psychology, Alliant International University, Alhambra, California. Dr. Saks is with the Gould School of Law and Dr. Brekke is with the School of Social Work, University of Southern California, Los Angeles.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1176/appi.ps.201600031DOI Listing
April 2017

An RCT Evaluating the Effects of Skills Training and Medication Type on Work Outcomes Among Patients With Schizophrenia.

Psychiatr Serv 2017 03 1;68(3):271-277. Epub 2016 Nov 1.

Dr. Glynn and Dr. Marder are with the U.S. Department of Veterans Affairs (VA) Greater Los Angeles Healthcare System, Los Angeles, and the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles (UCLA) (e-mail: ). Dr. Noordsy is with the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California. Mr. O'Keefe is a graduate student at Southern New Hampshire University, Manchester. Ms. Becker and Dr. Drake are with the Rockville Institute, Westat, Lebanon, New Hampshire. Dr. Sugar is with the Department of Biostatistics, Fielding School of Public Health, and with the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA. Dr. Noordsy, Mr. O'Keefe, Ms. Becker, and Dr. Drake were with the Department of Psychiatry, and Ms. Becker and Dr. Drake were also with the Department of Community and Family Medicine, Geisel School of Medicine at Dartmouth University, Hanover, at the time of this research.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1176/appi.ps.201500171DOI Listing
March 2017

The current conceptualization of negative symptoms in schizophrenia.

World Psychiatry 2017 Feb;16(1):14-24

Department of Psychiatry, University of Naples SUN, Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/wps.20385DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5269507PMC
February 2017

Older Brains are Different: Brain-Behavior Studies and Their Clinical Utility.

Am J Geriatr Psychiatry 2017 01 6;25(1):11-12. Epub 2016 Oct 6.

Psychiatry Service, VA Greater Los Angeles Healthcare System, Los Angeles, CA; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jagp.2016.10.002DOI Listing
January 2017

Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial.

Prog Neuropsychopharmacol Biol Psychiatry 2016 11 28;71:66-75. Epub 2016 Jun 28.

Novartis Pharma AG, Basel, Switzerland; Department of Neurology and Neurosurgery, McGill University, Montreal, Québec, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pnpbp.2016.06.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432789PMC
November 2016

Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research.

Biol Psychiatry 2016 07;80(2):84-86

Department of Psychiatry, University Neuropsychiatric Institute, University of Utah Health Sciences Center, Salt Lake City, Utah.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopsych.2016.05.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150945PMC
July 2016

Alpha-7 nicotinic agonist improves cognition in schizophrenia.

Authors:
Stephen R Marder

Evid Based Ment Health 2016 05 12;19(2):60. Epub 2016 Feb 12.

University of California, Los Angeles, Los Angeles, California, USA;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/eb-2015-102214DOI Listing
May 2016

Community Evidence of Clozapine's Effectiveness.

Authors:
Stephen R Marder

Am J Psychiatry 2016 Feb;173(2):103-4

From the Semel Institute for Neuroscience at UCLA and the Veterans Affairs Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1176/appi.ajp.2015.15111466DOI Listing
February 2016

Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 1—Psychometric Characteristics of 5 Paradigms.

Schizophr Bull 2015 Sep 3;41(5):1045-54. Epub 2015 Jul 3.

Department of Veterans Affairs VISN 22 Mental Illness Research, Education, and Clinical Center, Los Angeles, CA; UCLA Semel Institute for Neuroscience & Human Behavior, David Geffen School of Medicine, Los Angeles, CA;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/schbul/sbv089DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535649PMC
September 2015

Ellen Stover.

Neuropsychopharmacology 2014 Dec;39(13):3132

New York State Psychiatric Institute, Columbia University, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/npp.2014.252DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229591PMC
December 2014

Learning from people with schizophrenia.

Schizophr Bull 2014 Nov 27;40(6):1185-6. Epub 2014 Jun 27.

Department of Psychiatry, University of Colorado, Denver, Denver, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/schbul/sbu096DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4193727PMC
November 2014

Restrictive symptomatic inclusion criteria create barriers to clinical research in schizophrenia negative symptoms: an analysis of the CATIE dataset.

Eur Neuropsychopharmacol 2014 Oct 17;24(10):1615-21. Epub 2014 Aug 17.

Bar Ilan University, Ramat Gan, 22 Akiva Street, 43263 Raanana, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euroneuro.2014.08.004DOI Listing
October 2014

The reliability and validity of the MATRICS functional assessment battery.

Schizophr Bull 2014 Sep 9;40(5):1047-52. Epub 2013 Nov 9.

Semel Institute for Neuroscience, University of California, Los Angeles and VA Desert Pacific Mental Illness Research, Education and Clinical Center, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/schbul/sbt148DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133666PMC
September 2014

Oxytocin-augmented social cognitive skills training in schizophrenia.

Neuropsychopharmacology 2014 Aug 18;39(9):2070-7. Epub 2014 Mar 18.

1] Department of Psychiatry and Biobehavioral Sciences, UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA [2] VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/npp.2014.68DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104336PMC
August 2014

Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms.

Psychiatry Res 2014 Aug 13;218(1-2):219-24. Epub 2014 Apr 13.

Semel Institute for Neuroscience at UCLA and VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.psychres.2014.04.009DOI Listing
August 2014

Psychopharmacology of the negative symptoms: current status and prospects for progress.

Eur Neuropsychopharmacol 2014 May 4;24(5):788-99. Epub 2013 Nov 4.

Department of Veterans Affairs, VISN 22 Mental Illness Research, Education, and Clinical Center, Los Angeles, CA, USA; UCLA Semel Institute of Neuroscience and Human Behavior, Los Angeles, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euroneuro.2013.10.010DOI Listing
May 2014

Defining and measuring negative symptoms of schizophrenia in clinical trials.

Eur Neuropsychopharmacol 2014 May 11;24(5):737-43. Epub 2013 Nov 11.

Department of Psychiatry, School of Medicine, University of Nevada, Reno, NV, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euroneuro.2013.10.016DOI Listing
May 2014

Perspective: Retreat from the radical.

Authors:
Stephen R Marder

Nature 2014 Apr;508(7494):S18

Semel Institute for Neuroscience at the University of California, Los Angeles, and the VA Desert Pacific Mental Illness Research, Education and Clinical Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/508S18aDOI Listing
April 2014

Schizophrenia--time to commit to policy change.

Schizophr Bull 2014 Apr;40 Suppl 3:S165-94

*To whom correspondence should be addressed; Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria; tel: +43-512-504-23669, fax: +43-512-504-25267, e-mail:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/schbul/sbu006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4002061PMC
April 2014

Pharmacological approaches to treating negative symptoms: a review of clinical trials.

Schizophr Res 2013 Nov 9;150(2-3):346-52. Epub 2013 Aug 9.

Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, CIBERSAM, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.schres.2013.07.026DOI Listing
November 2013

Adapting social neuroscience measures for schizophrenia clinical trials, Part 2: trolling the depths of psychometric properties.

Schizophr Bull 2013 Nov 26;39(6):1201-10. Epub 2013 Sep 26.

*To whom correspondence should be addressed; VA Greater Los Angeles Healthcare Center (MIRECC 210 A), Building 210, Room 116, 11301 Wilshire Boulevard, Los Angeles, CA 90073, US; tel: 310-478-3711, ext. 49229, fax: 310-268-4056, e-mail:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/schbul/sbt127DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3796089PMC
November 2013

Adapting social neuroscience measures for schizophrenia clinical trials, part 3: fathoming external validity.

Schizophr Bull 2013 Nov 26;39(6):1211-8. Epub 2013 Sep 26.

*To whom correspondence should be addressed; Department of Psychology, Fordham University, Dealy Hall 216A, 441 East Fordham Road, Bronx, NY 10458-9993, US; tel: 919-259-1793, fax: 718-817-3785, e-mail:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/schbul/sbt130DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3796091PMC
November 2013

Clinical trials for negative symptoms--emerging directions and unresolved issues.

Schizophr Res 2013 Nov;150(2-3):327

Semel Institute for Neuroscience at UCLA and VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.schres.2013.10.005DOI Listing
November 2013

Monitoring treatment and managing adherence in schizophrenia.

Authors:
Stephen R Marder

J Clin Psychiatry 2013 Oct;74(10):e21

From the Department of Psychiatry and Behavioral Sciences, David Geffen School of Medicine; VA Desert Pacific Mental Illness Research, Education, and Clinical Center; and the Semel Institute, University of California, Los Angeles.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4088/JCP.12117tx2cDOI Listing
October 2013

Effects of single dose intranasal oxytocin on social cognition in schizophrenia.

Schizophr Res 2013 Jul 12;147(2-3):393-7. Epub 2013 May 12.

UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.schres.2013.04.023DOI Listing
July 2013

Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?

Schizophr Bull 2013 Mar 22;39(2):417-35. Epub 2011 Nov 22.

Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/schbul/sbr153DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576170PMC
March 2013

Clinical instruments to evaluate and guide treatment in schizophrenia.

Authors:
Stephen R Marder

Handb Exp Pharmacol 2012 (213):1-10

Veterans Affairs Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-642-25758-2_1DOI Listing
January 2013

Clinician perceptions, expectations, and management of negative symptoms in schizophrenia.

Authors:
Stephen R Marder

J Clin Psychiatry 2013 Jan;74(1):e01

Department of Psychiatry and Behavioral Sciences, David Geffen School of Medicine, Los Angeles.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4088/JCP.12045tx4cDOI Listing
January 2013

Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building.

J Pharmacokinet Pharmacodyn 2012 Aug 6;39(4):393-414. Epub 2012 Jul 6.

Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10928-012-9258-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400037PMC
August 2012

The cultural adaptability of intermediate measures of functional outcome in schizophrenia.

Schizophr Bull 2012 May 6;38(3):630-41. Epub 2010 Dec 6.

Department of Psychiatry, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/schbul/sbq136DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3329974PMC
May 2012

Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach.

J Clin Psychiatry 2011 Dec;72(12):1616-27

Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, USA.

View Article

Download full-text PDF

Source
http://article.psychiatrist.com/?ContentType=START&ID=10
Publisher Site
http://dx.doi.org/10.4088/JCP.11r06927DOI Listing
December 2011

The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?

Schizophr Bull 2011 Nov 21;37(6):1209-17. Epub 2010 Apr 21.

Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/schbul/sbq038DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3196938PMC
November 2011

Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study.

J Clin Pharmacol 2011 Nov 5;51(11):1587-91. Epub 2011 Jan 5.

Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0091270010387604DOI Listing
November 2011

Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia.

Schizophr Bull 2011 Sep 1;37(5):1057-65. Epub 2010 Mar 1.

Department of Psychiatry & Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/schbul/sbq010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3160227PMC
September 2011

Efficacy and specificity of social cognitive skills training for outpatients with psychotic disorders.

J Psychiatr Res 2011 Aug 4;45(8):1113-22. Epub 2011 Mar 4.

Department of Veterans Affairs VISN 22 Mental Illness Research, Education, and Clinical Center, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpsychires.2011.01.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064828PMC
August 2011

A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians.

Schizophr Bull 2011 May 23;37(3):538-45. Epub 2009 Sep 23.

Department of Behavioral Health, Philadelphia VA Medical Center, Rm 7A-113 Mail Code 116, PA 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/schbul/sbp095DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080688PMC
May 2011

Routine outcomes monitoring to support improving care for schizophrenia: report from the VA Mental Health QUERI.

Community Ment Health J 2011 Apr 25;47(2):123-35. Epub 2010 Jul 25.

VA Desert Pacific Mental Illness Research, Education and Clinical Center (MIRECC), West Los Angeles VA, 11301 Wilshire Boulevard, Los Angeles, CA 90073, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10597-010-9328-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058510PMC
April 2011

The brief negative symptom scale: psychometric properties.

Schizophr Bull 2011 Mar 17;37(2):300-5. Epub 2010 Jun 17.

Department of Psychiatry, Texas A&M College of Medicine, Temple, TX, USA.

View Article

Download full-text PDF

Source
https://academic.oup.com/schizophreniabulletin/article-looku
Publisher Site
http://dx.doi.org/10.1093/schbul/sbq059DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044634PMC
March 2011

Methodological issues in negative symptom trials.

Schizophr Bull 2011 Mar 26;37(2):250-4. Epub 2011 Jan 26.

The Semel Institute for Neuroscience at University of California, Los Angeles, CA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/schbul/sbq161DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044631PMC
March 2011

Lessons from MATRICS.

Authors:
Stephen R Marder

Schizophr Bull 2011 Mar 16;37(2):233-4. Epub 2011 Feb 16.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/schbul/sbq166DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044624PMC
March 2011

Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial.

J Clin Psychopharmacol 2010 Dec;30(6):683-7

Division of Clinical Pharmacology, Wishard Memorial Hospital, 1001 West 10th St, WD Meyers Building, W7123, Indianapolis, IN 46202, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/jcp.0b013e3181fa05bbDOI Listing
December 2010

Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation.

J Clin Psychiatry 2010 Apr 9;71(4):433-41. Epub 2010 Feb 9.

Building 210, Room 130, West Los Angeles VA Healthcare Center, 11301 Wilshire Blvd, Los Angeles, CA 90073, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4088/JCP.08m04411gryDOI Listing
April 2010

Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking.

J Clin Pharmacol 2010 Jan 20;50(1):73-80. Epub 2009 Oct 20.

Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania 46202, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0091270009343694DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3648660PMC
January 2010

Definitions of the term 'recovered' in schizophrenia and other disorders.

Psychopathology 2008 1;41(5):271-8. Epub 2008 Jul 1.

Department of Psychiatric Research, Ullevål University Hospital, Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000141921DOI Listing
March 2009

Psychosocial treatments to promote functional recovery in schizophrenia.

Schizophr Bull 2009 Mar 27;35(2):347-61. Epub 2009 Jan 27.

Veterans Affairs Greater Los Angeles Healthcare System (MIRECC 210 A), Building 210, Room 116, 11301 Wilshire Boulevard, Los Angeles, CA 90073, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/schbul/sbn177DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659313PMC
March 2009

The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.

J Clin Psychiatry 2009 Jan 2;70(1):25-35. Epub 2008 Dec 2.

Department of Psychiatry, Rush University Medical Center, Chicago, Illinoise 60612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4088/jcp.08m04310DOI Listing
January 2009

Better pharmacotherapy for schizophrenia: what does the future hold?

Curr Psychiatry Rep 2008 Aug;10(4):352-8

Semel Institute for Neuroscience at UCLA, Mental Illness Research, Education, and Clinical Center, VA West Los Angeles Health Care Center, MIRECC 210A, 11301 Wilshire Boulevard, Los Angeles, CA 90073-1003, USA.

View Article

Download full-text PDF

Source
August 2008

Treatment of agitation in patients with schizophrenia.

Authors:
Stephen R Marder

J Clin Psychiatry 2008 Jun;69(6):e17

Department of Psychiatry and Biobehavioral Sciences, Mental Illness Research, Education, and Clinical Center, West Los Angeles VA Healthcare Center, Los Angeles, Calif, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4088/jcp.0608e17DOI Listing
June 2008

Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia.

Prog Neuropsychopharmacol Biol Psychiatry 2008 May 18;32(4):984-8. Epub 2008 Jan 18.

Schizophrenia Research Group, Department of Psychiatry, Seoul National Hospital, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S027858460800022
Publisher Site
http://dx.doi.org/10.1016/j.pnpbp.2008.01.009DOI Listing
May 2008

It is time to take a stand for medical research and against terrorism targeting medical scientists.

Biol Psychiatry 2008 Apr;63(8):725-7

Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopsych.2008.03.005DOI Listing
April 2008

Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia.

Psychiatr Serv 2008 Mar;59(3):315-7

Eli Lilly and Company, Lilly Corporate Center Drop 4133, Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1176/ps.2008.59.3.315DOI Listing
March 2008

Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.

Am J Psychiatry 2008 Feb 2;165(2):221-8. Epub 2008 Jan 2.

Semel Institute for Neuroscience and Human Behavior, UCLA, 300 Medical Plaza, Rm. 2263, Los Angeles, CA 90095-6968, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1176/appi.ajp.2007.07010089DOI Listing
February 2008

The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.

Am J Psychiatry 2008 Feb 2;165(2):214-20. Epub 2008 Jan 2.

Department of Psychology, Geffen School of Medicine, University of California, Los Angeles CA 90073, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1176/appi.ajp.2007.07010043DOI Listing
February 2008

Sex, race, and smoking impact olanzapine exposure.

J Clin Pharmacol 2008 Feb;48(2):157-65

Department of Pharmaceutical Sciences, University of Pittsburgh, School of Pharmacy, 805 Salk Hall, 3501 Terrace St, Pittsburgh, PA 15261, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0091270007310385DOI Listing
February 2008

Chronic restlessness with antipsychotics.

Am J Psychiatry 2007 Nov;164(11):1648-54

San Diego VA Mental Illness Research, Education, and Clinical Center, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1176/appi.ajp.2007.07071150DOI Listing
November 2007